RYTM Earnings

RYTM reported its FY2025Q3 earnings on 2025-11-04, showcasing a revenue of 51.00M against an estimate of 51.00M, resulting in a 1.16% surprise. The EPS was -0.82, surpassing the expected -0.72 by -13.89% . The stock experienced a -7.69% price change on the earnings day and a -11.82% change over the next five days, reflecting market reactions to the results.

Following RYTM's FY2025Q3 earnings announcement on 2025-11-04, the stock price moved by -7.69% on the day of the release. Over the subsequent five days, it saw a -11.82% change. Historically, RYTM's stock price tends to shift by an average of -0.54% in the 10 days leading up to earnings and -2.14% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate RYTM’s annual revenue to reach 55.00M, while the EPS is projected at -1.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 0.85% and EPS estimates Revise Upward by 0.81% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between RYTM's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 0.85%, while EPS estimates moved Revise Upward by 0.81% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, RYTM's stock price typically moves by -0.54% in the 10 days before its earnings and -2.14% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -1.00 and revenue of 55.00M.

The company shows strong financial performance with a 54% YoY revenue increase and sustainable growth plans for BBS sales. The upcoming launch of IMCIVREE in hypothalamic obesity and positive payer feedback suggest potential market expansion. However, management's lack of clarity on certain aspects and the absence of a go/no-go decision for the PWS Phase III trial may cause some uncertainty. Considering the market cap, the overall sentiment is positive, predicting a 2% to 8% stock price increase over the next two weeks.